GEXVal Receives FDA Orphan Drug Designation for GXV-001 in Fragile X Syndrome
2025/11/19
GEXVal Inc.November 19, 2025 GEXVal Receives FDA Orphan Drug Designation for GXV-001 in Fragile X Syndrome GEX […]
GEXVal CEO to Speak at China Healthcare Summit 2025
2025/10/20
GEXVal Inc.October 20, 2025 GEXVal CEO Invited and to Speak at BioCentury-BayHelix China Healthcare Summit 2 […]
GEXVal CTO to Present at CBI Annual Meeting 2025
2025/10/17
GEXVal Inc.October 17, 2025 GEXVal CTO to Present at Chemo-Bio Informatics Society (CBI) Annual Meeting 2025 […]
GEXVal to Exhibit at BioJapan 2025
2025/10/3
GEXVal Inc.October 3, 2025 GEXVal to Showcase AI-Powered Drug Discovery Platform RePhaIND® at BioJapan 2025 […]